The approach of the proof is very similar to those in [17, 19, 20].
Further, the approach of the proof presented in this paper is also different.
The results presented in this paper are the supplement, extension, and generalization of results in the study of Plubtieng and Punpaeng and that of Cianciaruso et al. The approach of the proof given in this paper is also different.
The toxicology community should incorporate this emerging knowledge, whereby it can take an iterative approach of examining proof of concepts, assessing the value of new information, and developing decision rules.
Evidence of an effect, particularly if supported by opposing changes in proliferation and cell-cycle arrest markers, would act as initial corroboration of the normal tissue-based biomarker approach to proof of drug mechanism and dose/schedule finding described in the introduction to this paper.
Sun et al. made another approach to proof the formation of SBQDIRC.
Our approach offers proof-of-concept of a general strategy for creating a diverse array of peptide carriers for eventual therapeutic applications.
Thus, we conclude that our data demonstrate the technical feasibility and clinical potential of the riboleukogram approach, but proof of clinical utility will require further study.
To demonstrate the feasibility and effectiveness of the proposed approach, a proof-of-concept prototype system has been implemented in the JADE™ platform.
Indeed, although previous CDEPT work undoubtedly established the safety and feasibility of the approach, proof of in vivo antitumour efficacy has so far been limited (Lemmon et al, 1997; Theys et al, 2001a; Liu et al, 2002).
